Drug Trial Radar · NCT06149520
A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis
Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
283
Actual
Start
Jan 15, 2024
Primary completion
Oct 7, 2025
Study completion Dec 2, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Nov 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have deep vein thrombosis (DVT). DVT is a condition that occurs when a blood clot forms in a deep vein in the leg. DVT is called 'proximal' when the clot is formed in the veins of the hip, thigh, and knee. DVT can cause serious health problems. The blood clots in the veins can break loose and can then travel through the bloodstream and get stuck in the lungs, blocking blood flow to the lungs. Symptoms of DVT include swelling, pain, and tenderness in the affected leg, as well as redness and warmth in the area. Currently, DVT is usually treated using blood thinners to prevent the clot from getting bigger or breaking off and traveling to the lungs. However, blood thinners may not be able to remove a blood clot quickly and may not be suitable for everyone who has DVT. BAY3018250 is a drug that works by dissolving blood clots. In this study, researchers will compare BAY3018250 with placebo to learn how well it works and how safe it is in participants with proximal DVT. A placebo looks like the study drug but does not have any medicine in it. Using a placebo helps researchers to confirm that the results observed during the study were caused by the study drug and not by other factors. The main purposes of this study are to learn: * How well BAY3018250 works in dissolving blood clots in participants with proximal DVT and * How safe is BAY3018250 as a treatment for participants with proximal DVT? For this, the researchers will use ultrasound tests to measure blood clots in participants before and at various times after study treatment. They call these measurements a clot burden score. They will compare the clot burden score before and after treatment and will calculate a complex measure called AUC. This tells researchers how the clots have changed over time. And researchers will collect the number of bleeding events that require medical attention. The study participants will be randomly (by chance) assigned to one of 3 treatment groups. Dependent on the group, they will receive a single dose of high dose or low dose of BAY3018250 or placebo. Researchers will closely monitor participants for 90 days after receiving the study treatment. During the study, the doctors and their study team will: * take blood samples * do physical examinations * examine heart health using electrocardiogram (ECG) * check vital signs such as blood pressure, heart rate * undergo ultrasound tests to measure the blood clots * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.
Conditions
- Thrombolysis
- Symptomatic Proximal Deep Vein Thrombosis
Interventions
BAY3018250Drug
Dose 1 or dose 2 of BAY3018250
Placebo to BAY3018250Drug
Matching placebo to BAY3018250
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCn(6h-30d) of the ratio to baseline of clot burden, as assessed by repeated quantitative ultrasoundTime frame: at 6 hours, 24 hours, Day 7, Day 30
- Number of participants with composite of major and clinically relevant non-major (CRNM) bleeding events (ISTH definition)Time frame: up to Day 15
Locations
68 sites in 13 countries. Site status is shown where the registry gives one.
Universiteit Ziekenhuis Antwerpen | Thoraxheelkunde Afdeling
Antwerp, Belgium
Imelda - Vascular Surgery Dept
Bonheiden, Belgium
Ziekenhuis Oost-Limburg | Genk, Sint-Jan campus - Thoracic Vascular Surgery Department
Genk, Belgium
UZ Gent
Ghent, Belgium
AZ Groeninge - Campus Kennedylaan
Kortrijk, Belgium
Katholieke Universiteit Leuven (KU Leuven) - Center for Molecular and Vascular Biology (CMVB)
Leuven, Belgium
AZ Sint-Maarten
Mechelen, Belgium
University Multiprofile Hospital For Active Treatment Kanev AD
Rousse, Bulgaria
Specialized Hospital For Active Cardiology Treatment Medica Kor EAD
Rousse, Bulgaria
University Multiprofile Hospital For Active Treatment 'Alexandrovska' EAD
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment 'Sveta Ekaterina' EAD, Sofia
Sofia, Bulgaria
Medical Institute Ministry of Interior
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment Dr. Stefan Cherkezov | Base 1 - Cardiology Department
Veliko Tarnovo, Bulgaria
McGill University Health Centre - Glen Site
Montreal, Quebec, Canada
Vojenská nemocnice Brno - Interní oddelení, pododbor kardiologie
Brno, Czechia
Interni oddeleni, Krnovska nemocnice, Sdruzene zdravotnicke zarizeni Krnov, prispevkova organizace
Krnov, Czechia
Kardiologicka klinika, Fakultni nemocnice Kralovske Vinohrady
Prague, Czechia
Všeobecná fakultní nemocnice v Praze - II. interní klinika - klinika kardiologie a angiologie, AJIP
Prague, Czechia
Nemocnice Roudnice nad Labem - interni oddeleni
Roudnice nad Labem, Czechia
Interni a kardiologicka ambulance, Nemocnice Znojmo, prispevkova organizace
Znojmo, Czechia
Centre Hospitalier Universitaire Amiens Picardie Site Sud
Amiens Cedex1, France
Centre Hospitalier Regional Universitaire (CHRU) Brest - Hopital de la Cavale Blanche
Brest, France
Centre Hospitalier Universitaire de Clermont Ferrand - Gabriel Montpied
Clermont-Ferrand, France
Hôpital Louis Mourier - Colombes Cedex
Colombes, France
Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes) - Hopital Albert Michallon
La Tronche, France
AP-HP Hopital Europeen Georges-Pompidou (HEGP) - Service de medecine vasculaire
Paris, France
Centre Hospitalier Universitaire (CHU) de Saint-Etienne - Hopital Nord
Saint-Etienne, France
Hopitaux Universitaires de Strasbourg - Le Nouvel Hopital Civil (NHC)
Strasbourg, France
Hôpital Sainte Musse
Toulon, France
Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital de Rangueil - Service de medecine vasculaire
Toulouse, France
UNIVERSITAETSKLINIKUM FREIBURG - Universitaets-Herzzentrum Bad Krozingen | Klinik für Kardiologie und Angiologie
Bad Krozingen, Germany
Universitaetsklinikum Carl Gustav Carus an der Technischen Universitaet Dresden | Medizinische Klinik I - FB Haemostaseologie
Dresden, Germany
LMU Klinikum Campus Innenstadt | Medizinische Klinik und Poliklinik IV | FB Angiologie
München, Germany
Universitaetsklinikum Muenster | Klinik fuer Kardiologie I Sektion Angiologie
Münster, Germany
General Hospital Of Athens G Gennimatas- Department of Vascular Surgery
Athens, Greece
University General Hospital Attikon - 1st Department of Vascular surgery University of Athens
Athens, Greece
General Hospital Of Thessaloniki Papageorgiou- 1st Department of Surgery
Efkarpia, Greece
University General Hospital Of Ioannina- Department of Surgery, Vascular Unit Faculty
Ioannina, Greece
General University Hospital Of Patras- Department of Vascular Surgery
Pátrai, Greece
Bekes Varmegyei Kozponti Korhaz - Dr. Rethy Pal Tagkorhaz
Békéscsaba, Hungary
Showing 40 of 68 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.